Upfront Payment. In partial consideration for the exclusive licenses granted to GSK under the CureVac Technology, GSK shall pay to CureVac a non-refundable and non-creditable fee in the amount of seventy-five million Euro (EUR 75,000,000) within [*****] after the Closing Date. CureVac shall issue an invoice for that amount on or before the Closing Date.
Appears in 3 contracts
Samples: Covid Collaboration and License Agreement (CureVac N.V.), Covid Collaboration and License Agreement, Covid Collaboration and License Agreement (CureVac N.V.)
Upfront Payment. In partial consideration for the exclusive licenses granted to GSK under the CureVac Technology, GSK shall pay to CureVac a non-refundable and non-creditable fee in the amount of seventy-five one hundred and twenty million Euro (EUR 75,000,000120,000,000) within [*****] after the Closing Date. CureVac shall issue GSK's receipt of an invoice for that of the respective amount on or before the Closing Datefrom CureVac.
Appears in 2 contracts
Samples: Collaboration and License Agreement (CureVac B.V.), Collaboration and License Agreement (CureVac N.V.)
Upfront Payment. In partial consideration for the exclusive licenses granted to GSK under the CureVac Technology, GSK shall pay to CureVac a non-refundable and non-creditable fee in the amount of seventy-five million Euro (EUR 75,000,000) within [*****] after the Closing Date. CureVac shall issue an invoice for that amount on or before the Closing Date..
Appears in 1 contract
Upfront Payment. In partial consideration for the exclusive licenses granted to GSK under the CureVac Technology, GSK shall pay to CureVac a non-refundable and non-creditable fee in the amount of seventy-five one hundred and twenty million Euro (EUR 75,000,000120,000,000) within [*****] after the Closing Date. CureVac shall issue GSK’s receipt of an invoice for that of the respective amount on or before the Closing Datefrom CureVac.
Appears in 1 contract
